ELTX
Elicio Therapeutics, Inc. Common Stock
stockNASDAQ
elicio is committed to transforming the lives of patients and their families by re-engineering the body's immune response to cancer. by combining expertise in materials science and immunology, elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. the elicio amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the "brain center" of the immune response, to significantly amplify and enhance the body's own system of defenses, to defeat cancer and stop its recurrence. this substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. elicio's lead amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. elicio was founded to expand and apply the ground-breaking amphiphile technology invented and developed in the labs of darrell
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.85 | 2026-09-28 | +3.24% | 1.354 |
| 1M | 2.41 | 2026-09-04 | -20.75% | 2.227 |
| 3M | 3.30 | 2026-07-06 | -42.03% | 1.823 |
| 6M | 10.67 | 2026-04-06 | -82.10% | -1.206 |
| 1Y | 11.04 | 2025-10-03 | -82.70% | 0.324 |
| 2Y | 4.60 | 2024-10-04 | -58.48% | — |
| 5Y | 18.15 | 2023-06-02 | -89.47% | 0.406 |
Elicio Therapeutics, Inc. Common Stock (NASDAQ:ELTX) stock price today is $1.91, and today's volume is 175,963. ELTX is down 0.521% today. The 30 day average volume is 347,466. ELTX market cap is $50.20M with 26.28M shares outstanding.